Trending...
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- CCHR: New Data Shows Millions of U.S. Children Caught in Escalating Psychiatric Polypharmacy
- Dr. Johnny Shanks, As Seen on TV, Announces 20% Off Dental Implant Treatments | Tennessee's Leading All-on-X Provider
During PAD Awareness Month, Bend Oregon doctors urge people to get checked for peripheral artery disease and re-duce their risk of amputation.
BEND, Ore. - ncarol.com -- During the month of September, Peripheral Artery Disease (PAD) Awareness Month, Vascular Interventional Specialists of CORA will be partnering with other local medical providers in Central Oregon to promote awareness, screening, and treatment for PAD.
PAD is a chronic circulatory condition, which when left untreated can result in advanced disease and unnecessary limb amputation. PAD affects nearly 20 million Americans with an estimated 250,000 of them suffering avoidable amputation each year. A disproportionate number of these patients are from minority communities.
"PAD is a serious and yet often silent condition. Many patients don't have symptoms until the disease has advanced. That's why we want patients to be aware of health issues that contribute to the risk factors of PAD," said Dr. Benjamin English, Chief Vascular Specialist with Central Oregon Radiology Associates. By increasing PAD awareness in the Central Oregon community, Vascular Interventional Specialists of CORA hopes to improve access to screening and treatments, which has been shown to not only improve quality of life, but also dramatically lowers the risk of losing a limb.
More on ncarol.com
Dr English added that patients with diabetes, a history of smoking, high blood pressure, or high cholesterol are at greater risk for this condition. "We encourage patients to identify their risk and consider screening. Early detection and treatment is not only limb-saving, it can save lives as well," Dr. English stated.
For more information on PAD screenings, PAD doctors and treatment for PAD, visit: visofcora.com
PAD is a chronic circulatory condition, which when left untreated can result in advanced disease and unnecessary limb amputation. PAD affects nearly 20 million Americans with an estimated 250,000 of them suffering avoidable amputation each year. A disproportionate number of these patients are from minority communities.
"PAD is a serious and yet often silent condition. Many patients don't have symptoms until the disease has advanced. That's why we want patients to be aware of health issues that contribute to the risk factors of PAD," said Dr. Benjamin English, Chief Vascular Specialist with Central Oregon Radiology Associates. By increasing PAD awareness in the Central Oregon community, Vascular Interventional Specialists of CORA hopes to improve access to screening and treatments, which has been shown to not only improve quality of life, but also dramatically lowers the risk of losing a limb.
More on ncarol.com
- Mother Launches National Movement After College Athlete Hospitalized During Punishment Workout
- From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
- Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
- Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
- Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport
Dr English added that patients with diabetes, a history of smoking, high blood pressure, or high cholesterol are at greater risk for this condition. "We encourage patients to identify their risk and consider screening. Early detection and treatment is not only limb-saving, it can save lives as well," Dr. English stated.
For more information on PAD screenings, PAD doctors and treatment for PAD, visit: visofcora.com
Source: Vascular Interventional Specialists of CORA
Filed Under: Business
0 Comments
Latest on ncarol.com
- Orim Link Inc. Announces Official Launch, Bringing Modern Business Technology Solutions to Charlotte
- FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory
- Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
- "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
- Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
- Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
- High Rise: Path to Nowhere (2022) — A High-Stakes Thriller Filmed in Charlotte, North Carolina
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- 15,000+ Fans Expected at the 2026 BIG HBCU Southern Classic Battle of the Bands in Charlotte
- Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
- Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
- America's Most Festive Garages Wanted for Garage.com's 2025 Holiday Contest
- Railinc Launches RIGIS Routing+Mileage Application to Provide Accurate & Comprehensive Rail Routing
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough